Literature DB >> 26339369

Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.

Yang Lin1, Fangfang Liu1, Yu Fan1, Xiaolong Qian1, Ronggang Lang1, Feng Gu1, Jun Gu2, Li Fu1.   

Abstract

Pyruvate kinase M2 (PKM2) and vascular endothelial growth factor-C (VEGF-C) have been known to play an important role in tumorigenesis and tumor progression in breast cancer. However, the association between PKM2 and VEGF-C in breast cancer remains unclear. In the present study, a total of 218 specimens from breast cancer patients and 26 paired breast tumors with adjacent normal tissues as well as two breast cancer cell lines were enrolled to investigate the correlation between PKM2 and VEGF-C. We found that PKM2 and VEGF-C mRNA levels were both significantly increasing in breast tumors compared with adjacent normal tissues. Knockdown of PKM2 mRNA expression resulted in VEGF-C mRNA and protein down-regulated as well as cell proliferation inhibited. A positive correlation between PKM2 and VEGF-C expression was identified by immunohistochemical analyses of 218 specimens of patients with breast cancer (P=0.023). PKM2 high expression was significantly correlated with histological grade (P=0.030), lymph node stage (P=0.001), besides VEGF-C high expression was significantly associated with lymphovascular invasion (P=0.012). While combined high expression of PKM2 and VEGF-C was found to be associated with worse histological grade, more lymph node metastasis, more lymphovascular invasion, shorter progression free survival (PFS), and poorer overall survival (OS) in human breast cancer. The results of the present study suggested that PKM2 expression was correlated with VEGF-C expression, and combination of PKM2 and VEGF-C levels had the better prognostic significance in predicting the poor outcome of patients with breast cancer.

Entities:  

Keywords:  Breast cancer; pyruvate kinase M2; vascular endothelial growth factor-C

Mesh:

Substances:

Year:  2015        PMID: 26339369      PMCID: PMC4555697     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 2.  Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Authors:  Mayumi Tamada; Makoto Suematsu; Hideyuki Saya
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

3.  The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters.

Authors:  T Noguchi; K Yamada; H Inoue; T Matsuda; T Tanaka
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Xuelin Zhang; Chengzhi He; Chunya He; Baofu Chen; Yanxia Liu; Min Kong; Chunguo Wang; Lizhong Lin; Yan Dong; Haihui Sheng
Journal:  Pathol Res Pract       Date:  2013-06-28       Impact factor: 3.250

Review 5.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

Review 6.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Authors:  Sybille Mazurek
Journal:  Int J Biochem Cell Biol       Date:  2010-02-13       Impact factor: 5.085

7.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

8.  Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis.

Authors:  Liangwei Li; Yinwei Zhang; Jingjuan Qiao; Jenny J Yang; Zhi-Ren Liu
Journal:  J Biol Chem       Date:  2014-07-28       Impact factor: 5.157

9.  HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2.

Authors:  Alessandro Prigione; Nadine Rohwer; Sheila Hoffmann; Barbara Mlody; Katharina Drews; Raul Bukowiecki; Katharina Blümlein; Erich E Wanker; Markus Ralser; Thorsten Cramer; James Adjaye
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

10.  Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.

Authors:  Wen Hu; Shi-Xun Lu; Min Li; Chao Zhang; Li-Li Liu; Jia Fu; Jie-Tian Jin; Rong-Zhen Luo; Chris Zhiyi Zhang; Jing-Ping Yun
Journal:  Oncotarget       Date:  2015-03-30
View more
  9 in total

Review 1.  Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.

Authors:  Mohd Rihan; Lakshmi Vineela Nalla; Anil Dharavath; Amit Shard; Kiran Kalia; Amit Khairnar
Journal:  Cancer Microenviron       Date:  2019-06-10

2.  Expression and clinical significance of pyruvate kinase M2 in breast cancer: A protocol for meta-analysis and bioinformatics validation analysis.

Authors:  Huayan Li; Min Yan; Xiaoyong Wu; Yanliang Wang; Lin Huang
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

3.  Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis.

Authors:  Zhiqiao Zhang; Guanying Luo; Hongfeng Tang; Canchang Cheng; Peng Wang
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

4.  Prognostic significance of metabolic enzyme pyruvate kinase M2 in breast cancer: A meta-analysis.

Authors:  Yiming Yang; Ke Wu; Yulin Liu; Liang Shi; Kaixiong Tao; Guobin Wang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

5.  Prognostic significance and function of the vacuolar H+-ATPase subunit V1E1 in esophageal squamous cell carcinoma.

Authors:  Sung Wook Son; Seok-Hyung Kim; Eun-Yi Moon; Dong-Hoon Kim; Suhkneung Pyo; Sung Hee Um
Journal:  Oncotarget       Date:  2016-08-02

6.  Gene expression association study in feline mammary carcinomas.

Authors:  Daniela Ferreira; Bárbara Martins; Maria Soares; Jorge Correia; Filomena Adega; Fernando Ferreira; Raquel Chaves
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

7.  High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer.

Authors:  José Maañón; Diego Perez; Alejandro Rhode; Gonzalo Callejón; Francisco Rivas-Ruiz; Elisabeth Perez-Ruiz; Isabel Rodrigo; Belén Ramos; Francisco Medina; Rosa Villatoro; Maximino Redondo; Antonio Rueda
Journal:  Oncotarget       Date:  2018-06-15

Review 8.  Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods.

Authors:  Leila Hamzehzadeh; Meysam Yousefi; Seyed-Hamidollah Ghaffari
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-07-01

Review 9.  Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.

Authors:  Ming-Chuan Hsu; Wen-Chun Hung
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.